{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:34:13Z","timestamp":1776274453876,"version":"3.50.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,29]]},"abstract":"<jats:p>The use of immune checkpoint inhibitor (ICI) marked a revolutionary change in cancer treatment and opened new avenues for cancer therapy, but ICI can also trigger immune-related adverse events (irAEs). Here, we investigated the publicly available US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database to gain insight into the possible association between immune checkpoint inhibitors and hypophysitis. Data on adverse events (AEs) due to hypophysitisfor nivolumab, pembrolizumab, ipilimumab, and atezolizumab were collected from the US FDA Adverse Event Reporting System from the first quarter of 2004 to the second quarter of 2021, and the signals for hypophysitis associated with the four drugs were examined using the reporting odds ratio (ROR) method. The number of reported hypophysitis events\u2005\u2265\u20053 and the lower limit of the 95% confidence interval (CI) of the ROR\u2005&gt;\u20051 were considered positive for hypophysitis signals. A total of 1252 AE reports of hypophysitis associated with nivolumab, pembrolizumab, ipilimumab, and atezolizumab were collected, including 419, 149, 643, and 41 cases, respectively. The RORs of hypophysitis were 289.58 (95% CI 258.49\u2013324.40), 171.74 (95% CI 144.91\u2013203.54), 2248.57 (95% CI 2025.31\u20132496.45), and 97.29 (95% CI 71.28\u2013132.79), respectively. All four drugs were statistically correlated with the target AE, with the correlation being, in descending order, ipilimumab, nivolumab, pembrolizumab, and atezolizumab. Nivolumab, pembrolizumab, ipilimumab, and atezolizumab have all been associated with hypophysitis, which can negatively impact quality of life, and early recognition and management of immune checkpoint inhibitor-related hypophysitis is critical.<\/jats:p>","DOI":"10.1097\/md.0000000000037587","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T18:03:51Z","timestamp":1711735431000},"page":"e37587","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database"],"prefix":"10.1097","volume":"103","author":[{"given":"Qirui","family":"Tang","sequence":"first","affiliation":[{"name":"Clinical School of Medicine, Jining Medical University, Jining, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaru","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Jining City Hospital of Traditional Chinese Medicine, Jining, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Affiliated Hospital of Jining Medical University, Jining, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Affiliated Hospital of Jining Medical University, Jining, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Affiliated Hospital of Jining Medical University, Jining, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolei","family":"Ren","sequence":"additional","affiliation":[{"name":"Medical Big Data Center, Affiliated Hospital of Jining Medical University, Jining, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-4785","authenticated-orcid":false,"given":"Hailing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Affiliated Hospital of Jining Medical University, Jining, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events.","volume":"21","author":"Gonzalez-Rodriguez","year":"2016","journal-title":"Oncologist"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors.","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11060-021-03695-w","article-title":"Neurotoxicities associated with immune checkpoint inhibitor therapy.","volume":"152","author":"Duong","year":"2021","journal-title":"J Neurooncol"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy.","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R5-20250503","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study.","volume":"8","author":"Kobayashi","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints.","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12902-022-01024-4","article-title":"Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma.","volume":"22","author":"Yamada","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1272\/jnms.JNMS.2023_90-215","article-title":"Immune checkpoint inhibitors and associated pituitary dysfunctions: a mini-review.","volume":"90","author":"Fukuda","year":"2023","journal-title":"J Nippon Med Sch"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11060-020-03687-2","article-title":"Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.","volume":"152","author":"Mikami","year":"2021","journal-title":"J Neurooncol"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.","volume":"7","author":"Zhai","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis.","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2174\/1570159X19666201230151224","article-title":"Immune checkpoint inhibitors and neurotoxicity.","volume":"19","author":"Zhao","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/j.seminoncol.2010.09.004","article-title":"Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.","volume":"37","author":"Boasberg","year":"2010","journal-title":"Semin Oncol"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/jim-2021-002099","article-title":"Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort.","volume":"70","author":"Kotwal","year":"2023","journal-title":"J Investig Med"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MED.0000000000000652","article-title":"Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management.","volume":"28","author":"Kotwal","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"R19-20250503","first-page":"1","article-title":"Chinese expert consensus on the immune checkpoint inhibitors-induced endocrine immune-related adverse events (2020) (Chinese writing).","volume":"37","year":"2021","journal-title":"Chin J Endocrinol Metab"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes.","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-12-0167","article-title":"Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.","volume":"167","author":"Juszczak","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1592\/phco.24.8.743.36068","article-title":"Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States food and drug administration.","volume":"24","author":"Hartnell","year":"2004","journal-title":"Pharmacotherapy"},{"key":"R23-20250503","first-page":"123","article-title":"Analysis on the risk of diabetes mellitus related to immune checkpoint inhibitors based on the US FDA adverse event reporting system (Chinese writing).","volume":"24","author":"Peng","year":"2022","journal-title":"ADRJ"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","article-title":"Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.","volume":"30","author":"Pariente","year":"2007","journal-title":"Drug Saf"},{"key":"R25-20250503","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.836859","article-title":"Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function.","volume":"12","author":"Jessel","year":"2022","journal-title":"Front Oncol"},{"key":"R26-20250503","doi-asserted-by":"crossref","DOI":"10.3390\/medicina59111963","article-title":"Pituitary-related adverse events and onset patterns caused by immune checkpoint inhibitors: analysis using the Japanese adverse drug event report database.","volume":"59","author":"Asano","year":"2023","journal-title":"Medicina"},{"key":"R27-20250503","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-018-0810-1","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management.","volume":"18","author":"Astaras","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/17446651.2019.1598260","article-title":"Hypophysitis in the era of immune checkpoint inhibitors and immunoglobulin G4-related disease.","volume":"14","author":"Wehbeh","year":"2019","journal-title":"Expert Rev Endocrinol Metab"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1530\/EJE-19-0169","article-title":"Management of endocrine disease: immune check point inhibitors-induced hypophysitis.","volume":"181","author":"Albarel","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.","volume":"9","author":"Stelmachowska-Banas","year":"2020","journal-title":"Endocr Connect"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"209","DOI":"10.20344\/amp.13673","article-title":"Endocrinopathies associated with immune checkpoint inhibitors.","volume":"35","author":"Santos","year":"2022","journal-title":"Acta Med Port"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1210\/clinem\/dgac161","article-title":"Endocrine autoantibodies determine immune checkpoint inhibitor-induced endocrinopathy: a prospective study.","volume":"107","author":"Labadzhyan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R34-20250503","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source.","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jdi.13481","article-title":"Do sodium-glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real-world study.","volume":"12","author":"Zhao","year":"2021","journal-title":"J Diabetes Investig"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.2217\/imt-2021-0068","article-title":"Association between PD-L1 inhibitor, tumor site and adverse events of potential immune etiology within the US FDA adverse event reporting system.","volume":"13","author":"Abdel-Rahman","year":"2021","journal-title":"Immunotherapy"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T23:01:35Z","timestamp":1746313295000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":36,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037587","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,29]]}}}